NCT00952484View on ClinicalTrials.gov

Safety and Efficacy of Asfotase Alfa in Juvenile Patients With Hypophosphatasia (HPP)

PHASE2CompletedINTERVENTIONAL
Enrollment

13

Participants

Timeline

Start Date

September 30, 2009

Primary Completion Date

July 31, 2010

Study Completion Date

July 31, 2010

Conditions
Hypophosphatasia (HPP)
Interventions
BIOLOGICAL

asfotase alfa

2 mg/kg subcutaneous injection three times per week for 6 months.

BIOLOGICAL

asfotase alfa

3 mg/kg subcutaneous injection three times per week for 6 months.

Trial Locations (2)

63131

Shriners Hospital for Children, St Louis

R3A 1S1

The University of Manitoba Health Services Centre, Winnipeg

Sponsors
All Listed Sponsors
lead

Alexion Pharmaceuticals, Inc.

INDUSTRY